July 12, 2023 : AscellaHealth LLC, a prominent global healthcare and specialty pharmacy solutions company, has supported NeuroSolv Therapeutics LLC in advancing the clinical development and commercialization of Perineline™, a non-surgical therapy for spinal cord injury (SCI) patients. The partnership aims to enhance treatment options by addressing the formation of Glial scars and intervening in neural signaling to potentially restore bodily functions.
The concept for Perineline™ was initiated by Ros Lynch, co-founder of NeuroSolv, and his father, Aidan Lynch, CEO of NeuroSolv after Ros himself experienced an SCI. Recognizing the need for improved therapies, Ros Lynch expresses strong support from the SCI community for advancements in this field. The therapy, which has received Orphan designation from the European Medicines Agency, shows significant potential based on research conducted by neuro glyco scientist Dr. Jessica Kwok.
NeuroSolv is seeking financial investors and plans to conduct clinical trials and pre-commercialization activities for Perineline™. The company also aims to collaborate with leading pharmaceutical manufacturers for product development. Interested parties can reach out to Aidan Lynch for more information.
To raise awareness about Perineline™, NeuroSolv engages with spinal trauma hospitals, a global SCI research foundation, sports injury organizations, workers’ compensation insurers, auto insurance providers, rehabilitation hospitals, and the US Department of Veterans Affairs.
SCI affects approximately 17,000 individuals in the US annually, with motor vehicle collisions being the leading cause (38% of cases). AscellaHealth EU/UK’s executive vice president, Craig Caceci, highlights their comprehensive support throughout the product life cycle, focusing on clinical trials, market access, distribution, and more.
AscellaHealth aims to enhance medication access, reduce costs, and improve patient outcomes. Caceci expresses pride in serving as a strategic resource for NeuroSolv, providing hope for SCI patients worldwide.